Kala Bio (KALA) Common Equity (2016 - 2026)
Kala Bio (KALA) posted Common Equity of $10.8 million for Q1 2026, up 53.82% sequentially from $7.0 million in Q4 2025, and up 88.52% YoY from $5.7 million in Q1 2025.
Kala Bio (KALA) Common Equity (2016 - 2026) Analysis & Trends
Kala Bio has reported Common Equity for 11 years, with the latest figure at $10.8 million in Q1 2026.
- Quarterly Common Equity rose 88.52% year-over-year to $10.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.8 million (up 88.52% YoY) and the FY2025 annual result came in at $7.0 million, down 43.27% from the prior year.
- Common Equity climbed to $10.8 million in Q1 2026 per KALA's latest filing, from $7.0 million in the prior quarter.
- Over five years, Common Equity peaked at $23.5 million in Q1 2023 and troughed at -$31.6 million in Q2 2022.
- A 5-year average of $5.4 million and a median of $7.0 million in 2025 frame the typical range for Common Equity.
- The sharpest annual moves came in 2023 and 2025: Common Equity soared 1259.4% in 2023, then tumbled 226.33% in 2025.
- Over 5 years, Common Equity stood at $19.0 million in 2022, then plunged by 60.45% to $7.5 million in 2023, then soared by 64.34% to $12.3 million in 2024, then plunged by 43.27% to $7.0 million in 2025, then jumped by 53.82% to $10.8 million in 2026.
- According to Business Quant data, Common Equity over the past three periods registered $10.8 million, $7.0 million, and -$8.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.35 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 757.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.79 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 22.38 Bn |
| 10 | Kala Bio | 9.87 Mn | 9.87 Mn | - | 10.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10.76 Mn |
| Dec 31, 2025 | 7.00 Mn |
| Sep 30, 2025 | -8.67 Mn |
| Jun 30, 2025 | -3.21 Mn |
| Mar 31, 2025 | 5.71 Mn |
| Dec 31, 2024 | 12.33 Mn |
| Sep 30, 2024 | 6.86 Mn |
| Jun 30, 2024 | 13.72 Mn |
| Mar 31, 2024 | 6.66 Mn |
| Dec 31, 2023 | 7.50 Mn |
| Sep 30, 2023 | 11.22 Mn |
| Jun 30, 2023 | 17.49 Mn |
| Mar 31, 2023 | 23.46 Mn |
| Dec 31, 2022 | 18.97 Mn |
| Sep 30, 2022 | -968,000.00 |
| Jun 30, 2022 | -31.55 Mn |
| Mar 31, 2022 | -5.28 Mn |
| Dec 31, 2021 | 16.80 Mn |
| Sep 30, 2021 | 61.47 Mn |
| Jun 30, 2021 | 84.27 Mn |